ASX:CU6Pharmaceuticals
Clarity Pharmaceuticals H1 2026 Loss Worsening Challenges Bullish Profitability Narrative
Clarity Pharmaceuticals (ASX:CU6) has posted its H1 2026 scorecard, with investors watching how its revenue base and per share losses are tracking against ambitious growth expectations. The company has seen half year revenue move from A$6.1 million in H2 2024 to A$4.7 million in H1 2025 and A$4.8 million in H2 2025. Over the same periods, basic EPS moved from a loss of A$0.09 per share in H2 2024 to losses of A$0.07 in H1 2025 and A$0.13 in H2 2025. This sets the scene for a results season...